Cardlytics Q3 Adj EPS $(0.01), Inline, Sales $79.00M Miss $80.01M Estimate
Portfolio Pulse from bharat@benzinga.com
Cardlytics (NASDAQ:CDLX) reported Q3 adjusted EPS of $(0.01), in line with analyst consensus. However, the company's sales of $79.00M missed the estimate of $80.01M. This represents a 98% increase in EPS and an 8.66% increase in sales compared to the same period last year.
November 08, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cardlytics reported Q3 results in line with EPS estimates but missed on sales. The company showed significant YoY growth in both EPS and sales.
Cardlytics' Q3 results were mixed with EPS meeting estimates but sales falling short. However, the YoY growth in both EPS and sales is a positive sign. The impact on the stock price could be neutral in the short term as the positive and negative factors balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100